India, Aug. 6 -- Odyssey Therapeutics Inc. (ODTX), a clinical-stage biopharmaceutical company, on Tuesday announced financial results for the second quarter, and recorded a higher net loss due to increased spending on external Research and Development for the company's preclinical and clinical programs.
Odyssey specializes in the discovery and design of therapies that target the specific pathologies of autoimmune or inflammatory diseases. The company began trading on the Nasdaq Capital Market in May 2026.
Q2 Financial Highlights:
The company reported a net loss of $52.8 million, about 28% higher than the second quarter loss of $41.2 million in the previous year.
R&D expenses amounted to $36.2 million, while in 2025 the same was $30.2 mi...